Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q3 EPS by 26c

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q3 EPS of ($0.96), $0.26 better than the analyst estimate of ($1.22).

For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79